E
CLYM

Ergoteles’s Climb Bio CLYM Stock Holding History

Ergoteles’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,364
Closed -$80K – 2062
2022
Q2 		$80K Buy
+26,364
New +$125K ﹤0.01% 1535

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's CLYM Position: Q3 2022 in Review

Ergoteles sold out of Climb Bio (CLYM) in Q3 2022, closing a stake of 26,364 shares — an estimated $80K sold.

Ergoteles first reported a position in CLYM in Q2 2022 and held it in 1 quarter. The position peaked at $80K in Q2 2022. 22 funds tracked by Wall St. Rank hold CLYM as of Q3 2022.

  • Ergoteles reported no remaining Climb Bio position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 26,364 Climb Bio shares in Q3 2022, an estimated $80K.
  • Ergoteles first reported a position in Climb Bio in Q2 2022 and held it in 1 quarter.
  • Ergoteles's Climb Bio position peaked at $80K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Climb Bio as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.